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Abstract
The alternative transcription factor s
B is responsible for transcription in Staphylococcus aureus during the stress response.
Many virulence-associated genes are directly or indirectly regulated by s
B. We hypothesized that treatment with antibiotics
may act as an environmental stressor that induces s
B activity in antibiotic-resistant strains. Several antibiotics with distinct
modes of action, including ampicillin (12 mg/ml), vancomycin (16 or 32 mg/ml), chloramphenicol (15 mg/ml), ciprofloxacin
(0.25 mg/ml), and sulfamethoxazole/trimethoprim (SXT, 0.8 mg/ml), were investigated for their ability to activate this
transcription factor. We were especially interested in the stress response in vancomycin-resistant S. aureus (VRSA) strains
treated with vancomycin. The transcription levels of selected genes associated with virulence were also measured. Real-time
quantitative reverse transcription PCR was employed to evaluate gene transcription levels. Contact hemolytic and
cytotoxicity assays were used to evaluate cell damage following antibiotic treatment. Antibiotics that target the cell wall
(vancomycin and ampicillin) and SXT induced s
B activity in VRSA strains. Expression of s
B-regulated virulence genes,
including hla and fnbA, was associated with the vancomycin-induced s
B activity in VRSA strains and the increase in
cytotoxicity upon vancomycin treatment. These effects were not observed in the sigB-deficient strain but were observed in
the complemented strain. We demonstrate that sub-minimum inhibitory concentration (sub-MIC) levels of antibiotics act as
environmental stressors and activate the stress response sigma factor, s
B. The improper use of antibiotics may alter the
expression of virulence factors through the activation of s
B in drug-resistant strains of S. aureus and lead to worse clinical
outcomes.
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Introduction
Vancomycin is used to treat health care-associated infections
resulting from multidrug-resistant S. aureus, including methicillin-
resistant S. aureus (MRSA). The first clinical case of vancomycin-
intermediate S. aureus (VISA) was reported in 1997, followed by the
appearance of the first vanA-mediated vancomycin-resistant S.
aureus (VRSA) clinical isolate in 2002 [1–3]. A recent study in
Taiwan indicated that 2.9% of the MRSA strains isolated were
VISA [4].
We are interested in studying the role of an antibiotic when
applied to a resistant strain of bacteria. Such an antibiotic may no
longer be lethal (or inhibit growth) but instead acts as a stimulus
(stress) to drug-resistant strains. If so, whether this type of stress
activates s
B and thereby affects the expression of downstream
virulence factors remains to be determined. s
B is the alternative s
factor that modulates the general stress response in certain Gram-
positive bacteria, including Bacillus subtilis, Listeria monocytogenes, and
S. aureus [5]. In addition to the general stress response, s
B regulates
cell wall metabolism, membrane transport processes and virulence
in S. aureus [6,7]. It has also been shown that virulence factors, such
as a-hemolysin (encoded by hla) and fibronectin-binding protein A
(encoded by fnbA), are likely controlled by s
B through the global
regulator SarA and/or the agr locus [8,9]. Recently, it was
demonstrated that s
B plays a role in central venous catheter
(CVC)-associated infections [10].
Concentrations of antibiotics below the minimum inhibitory
concentration (MIC) are known to promote a variety of bacterial
properties, such as the alternation of virulence; the effects of sub-
MICs do not necessarily involve a reduction in the growth rate
[11]. It has been reported that sub-MICs of b-lactam antibiotics
induce the expression of virulence-associated exotoxin genes in S.
aureus [12]. In Clostridium difficile, another opportunistic pathogenic
Gram-positive bacterium, the transcription of major virulence
factor genes is induced by sub-MICs of antibiotics [13]. However,
sub-MICs of protein synthesis-suppressing antibiotics, such as
PLoS ONE | www.plosone.org 1 September 2011 | Volume 6 | Issue 9 | e24472clindamycin, linezolid and quinupristin/dalfopristin, have been
shown to inhibit virulence factors released by S. aureus [14–16].
In the present study, we hypothesized that s
B may respond to
antibiotic stress and mediate the stress signal to downstream
virulence factors in antibiotic-resistant S. aureus strains. Antibiotics
with distinct modes of action were used to investigate their
potential in activating s
B. The drugs used in this study were
ampicillin b-lactam; targets the cell wall), vancomycin (glycopep-
tide; targets the cell wall), chloramphenicol (suppresses protein
synthesis), ciprofloxacin (suppresses DNA synthesis), and SXT
(interferes with folic acid metabolism). Because vancomycin is used
to treat infections caused by MRSA, the effect of vancomycin
treatment on cytotoxicity and the expression of selected virulence
genes was tested in VRSA strains.
Materials and Methods
Bacterial strains, plasmids and growth conditions
The bacterial strains, plasmids and primers used in this study
are listed in Table 1 and Table 2. All bacterial strains were
routinely cultured at 37uC with the specific required antibiotics
(Sigma) in BHI broth (for S. aureus), in LB broth (for E. coli)o ro n
agar plates. The plasmids used to transform S. aureus strains were
maintained in strain RN4220 prior to conducting the experiments.
The vancomycin-resistant S. aureus strain SJC1200 was
generated by introducing a vancomycin resistance-carrying
plasmid (pG1546) into strain ATCC 12598 as described previously
[17]. The PRvanRSPHHAXPYvanYPZvanZ gene cluster (the van
operon within Tn1546)i nE. faecalis HIP12467 was amplified
using the primer pair Tn-SphI-F and Tn-KpnI-R, which
contained restriction sites for SphI and KpnI. The 7075-bp PCR
product was then cloned into pGHL6 from which the luxAB gene
was removed by digestion with the same restriction enzymes (New
England Biolabs) to generate pG1546. VRSA strains, approved by
the Chang Gung University biosafety committee, were used
strictly in a P2 level laboratory, and all lab equipment and surfaces
were sterilized by bleach and/or autoclaved immediately after the
experiments were performed.
Allelic replacement of the sigB gene by a spectinomycin cassette
(spc) was performed by introducing the pMASigBD plasmid into
strain SJC1200 to generate the sigB mutant strain SJC1205, as
described previously [18]. A spectinomycin cassette restricted by
NcoI and SalI was flanked by the upstream and downstream arms
of the PCR product. The 1115-bp upstream arm originating from
the 59 end of the sigB was amplified using the primer pair RsbU-
BglII-F and SigB-NcoI-R, which contained BglII and NcoI
restriction sites, respectively. The 1183-bp downstream arm
restricted by SalI and BamHI was amplified using the primer pair
SigB-SalI-F and SA2151-BamHI-R from the 39 end of sigB. The
constructed upstream arm-spc-downstream arm DNA fragment
restricted by BglII and BamHI was then cloned into pMAD,
yielding pMASigBD.
Complementation of the sigB mutation in strain SJC1205 was
performed by inserting the full-length rsbU and sigB operon
(PUrsbUPVrsbVWsigB), including the promoter region, into the rocA
gene via homologous recombination to generate SJC1206 [19].
The 3277-bp PUrsbUPVrsbVWsigB DNA fragment restricted by SalI
and NcoI was amplified using the primer pair SigBop-SalI-F and
SigBop-NcoI-R and was flanked by parts of the 59 and 39 ends of
rocA. The 484-bp 59 region was amplified using the primer pair
RocA-BamHI-F and RocA-SalI-R, whereas the 489-bp 39 region
was amplified using RocA-NcoI-F and RocA-BglII-R. The 59
region-PUrsbUPVrsbVWsigB-39 region DNA fragment was cloned
into pMAD, yielding pMAsigBC, which was then used to
transform into SJC1205. The sigB-complemented colonies were
selected using blue-white screening at the non-permissive temper-
ature [18]. The insertion of rocA by PUrsbUPVrsbVWsigB was
confirmed by PCR and DNA sequencing.
Detection of gene expression and real-time quantitative
reverse transcription PCR (qRT-PCR)
The activity of s
B upon treatment with antibiotics with distinct
modes of action was detected using RT-PCR by assaying the
transcription of asp23, a gene encoding an alkaline shock protein,
which is directly activated by s
B [20]. The MICs of the antibiotics
used in the present study were determined by an E-test and a
microdilution broth method according to CLSI guidelines [21].
The MICs of the antibiotics for strain SJC1200, and the final
concentrations used in the qRT-PCR assay are provided in
Table 3. Antibiotics were added to bacterial cultures at the
indicated concentrations at OD600=0.6. Antibiotic-treated or
untreated bacterial cells were collected and pelleted at a given time
and frozen on dry ice immediately. Total RNA was extracted from
cell pellets using TRIzol (Invitrogen) followed by RQ1 RNase-free
DNase (Promega) treatment to eliminate any remaining DNA. An
RT-PCR time course was performed, and the results were
visualized using agarose gel electrophoresis to determine the time
points for subsequent qRT-PCR analysis. The mRNA levels,
including those of sigB, asp23, fnbA and hla, upon vancomycin
treatment (32 mg/ml) were determined by qRT-PCR with the
KAPA
TM SYBRH qPCR Kit (Kapa Biosystems) in a Roche
LightCycler (LC-32). All samples were tested in triplicate in three
independent experiments. The expression levels of different genes
were normalized against the dnaA expression level. The fold
change of each transcript was determined by the 2
2DDCT method
compared with the untreated cells [22].
Table 1. Bacterial strains and plasmids used in this study.
Strain or plasmid Description
a
Reference
or source
Strains
Escherichia coli
DH5a General molecular cloning Invitrogen
Enterococcus faecalis
HIP12467 pAM830::Tn1546;V a n
R NARSA
b [35]
Staphylococcus aureus
RN4220 Plasmids reservation NARSA
ATCC12598 Standard strain ATCC
SJC1200 ATCC12598/pG1546; Van
R This study
SJC1205 SJC1200, DsigB::spc;V a n
R,S p c
R This study
SJC1206 SJC1205, rocA:: sigB operon;
Van
R,S p c
R
This study
Plasmids
pGHL6 E. coli/S. aureus shuttle vector [36]
pG1546 pGHL6/DluxAB::van operon This study
pMAD Vector for allelic replacement [18]
pMAsigBD pMAD/sigB::spc This study
pMAsigBC pMAD/rocA::sigB operon This study
aAbbreviations: Van
R, vancomycin resistant; Spc
R, spectinomycin resistant.
bNetwork on Antimicrobial Resistance in Staphylococcus aureus (NARSA).
doi:10.1371/journal.pone.0024472.t001
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Contact hemolysis was performed as described elsewhere [23].
The bacteria were cultured overnight, diluted to OD600 =0.1 and
subcultured in 20 ml of fresh LB Broth for about three hours at
37uC at which point the culture was in log phase
(OD600=0.6,0.8). The bacterial cultures were collected by
centrifugation at 10,0006g for 10 minutes at 4uC and resuspended
in 20 ml of cold PBS. Sheep blood was washed three times in PBS
by centrifugation at 1,5006g for five minutes at 4uC and diluted to
a final concentration of 8%. A 100 ml aliquot of bacterial culture
was mixed with 900 ml of 8% red blood cells (10-fold dilution of
bacteria) in a 1.5 ml centrifuge tube and incubated at 37uC for
three hours. Finally, the mixtures were centrifuged at 1,5006g for
10 min at 4uC, and the OD450 was measured using a Novaspec II
spectrophotometer (Pharmacia Biotech). The positive control
sample contained erythrocytes that had been lysed by SDS. One
unit of hemolytic activity was defined as half of the total
erythrocytes lysed by hemolysin relative to the positive control at
OD450, followed by multiplication by the dilution factor to obtain
the final hemolytic unit.
Cytotoxicity assay
The cytotoxicity assay was performed by evaluating the cell
viability of BEAS-2B cells (human bronchial epithelial cells) co-
cultured with S. aureus in the presence of different concentrations of
vancomycin. BEAS-2B cells were maintained in RPMI-1640
medium (Gibco BRL) supplemented with 10% fetal bovine serum,
10% glycine and 1% penicillin and streptomycin at 37uCi na
humidified atmosphere of air and 5% CO2. Cell viability tests
were performed using the MTT assay with the cell proliferation
reagent MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazoli-
um bromide; Sigma), as described previously [24]. The MTT
tetrazolium ring is cleaved only by active mitochondria, yielding
purple formazan crystals whose amount directly correlates with
the viable cell count. Cells were inoculated with different S. aureus
strains (multiplicity of infection of 100) in the presence of different
concentrations of vancomycin. In a parallel experiment, polyclonal
fibronectin antibodies (5 mg/ml; Abcam) were added to block the
interaction between fibronectin-binding proteins and cells. After
six hours of exposure, 10 ml of a 5 mg/ml MTT solution was
added into each well, and the plates were incubated at 37uC for
2.5 hours. The purple formazan crystals were dissolved by adding
100 ml of MTT solubilization solution (Sigma), and the absorbance
at A570 was spectrophotometrically measured with a reference
wavelength of A690. The results were expressed as the percent
absorbance of the vancomycin-treated cultures versus the
untreated control cultures. Three wells per dose were counted in
three independent experiments.
Statistical analysis
A Student’s t-test was used to analyze the experimental data and
to compare means. P values of less than 0.05 were considered
statistically significant.
Results
Effect of antibiotic treatment on the expression of s
B
Strain SJC1200 was treated with antibiotics with distinct modes
of action at sub-inhibitory concentrations as shown in Table 3.
Bacterial growth was assessed by monitoring the growth curve
spectrophotometrically at OD600. The plateau level was not
affected by antibiotic treatment, but the stationary phase was
reached later than in the drug-free condition (data not shown).
The expression of asp23, which is directly activated by s
B, was
increased at 10 minutes post-treatment with ampicillin, vancomy-
cin, and SXT (Fig. 1).
We next focused on the effects of vancomycin treatment on the
expression of sigB using real-time qRT-PCR. It had been
recommended that the appropriate therapeutic range of vanco-
mycin concentrations in the serum is 15 to 20 mg/ml for through
levels and 20 to 40 mg/ml for peak levels [25]. A recent study also
indicated that 74% of heteroresistant VISA (hVISA) strains and
15% of wild-type S. aureus strains were tolerant to the effects of
vancomycin (minimum bactericidal concentration of § 32 mg/ml)
Table 3. MICs of antibiotics for strain SJC1200 and the final
concentrations treated in qRT-PCR for all of the tested strains.
Antibiotic
a
Van Amp Cm Cip SXT
MIC
b (mg/ml) .256 32 64 0.8 2
Treated concentration
c
(mg/ml)
16 or 32 12 16 0.25 0.8
aAbbreviations: Van: vancomycin; Amp: ampicillin; Cm: chloramphenicol; Cip:
ciprofloxacin; SXT: sulfamethoxazole/trimethoprim.
bThe MICs of antibiotics for strains SJC1205 and 1206 were the same as for
SJC1200.
cThe concentrations used were based on the therapeutic levels except for SXT.
doi:10.1371/journal.pone.0024472.t003
Table 2. Primers used in this study.
Primer Sequence (59 R 39)
a
Cloning
Tn-SphI-F AAAGCATGCAGGAATGAATTATGCGG
Tn-KpnI-R CACTTGGTACCTACGGGCGAGTTTC
RsbU-BglII-F CGGAAGATCTGACTGAAGCTAG
SigB-NcoI-R GCTCAGGTGAAACTTCCATGGCTGATTTC
SigB-SalI-F CGTCGACTAAGAAATTACAAGAAGCAGC
SA2151-BamHI-R TTCTTGACGTGCAATGGGATCCTCAC
SigBop-SalI-F CGGTCGACTATTGAAAATGACACACCATC
SigBop-NcoI-R AACCATGGCGTCTATTATATGTATTTTTCAGAG
RocA-BamHI-F CCTGGATCCACACCTAAGATGTG
RocA-SalI-R CATGTGAATGGTCGACATTTAAAC
RocA-NcoI-F CTGTTATGCATATACCATGGTC
RocA-BglII-R GCATTAGAACAGATCTGAAACAACC
qRT-PCR
sigB-F TGGCGAAAGAGTCGAAATCAGC
sigB-R TCAGCGGTTAGTTCATCGCTCAC
asp23-F AAAATTGCTGGTATCGCTGC
asp23-R TGTAAACCTTGTCTTTCTTGGT
fnbA-F ACTGGCGCAGTGAGCGACCA
fnbA-R GCACTTCTGGCGTTGGCGGT
hla-F CCTGGCCTTCAGCATTTAAG
hla-R GGTCCCCAATTTTGATTCAC
dnaA-F TCCACATGCAGCGAGTTTAG
dnaA-R GGTGGTCGATCACTCGAAAT
aIncorporated restriction sites are underlined.
doi:10.1371/journal.pone.0024472.t002
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in our experiments was 32 mg/ml. Over the time course examined,
the RT-PCR results showed that the peak expression of sigB and
asp23 was five and 10 minutes after vancomycin treatment,
respectively, and samples were collected for subsequent qRT-PCR
assays at these time points (Fig. S1). The results shown in Fig. 2A
indicate that the expression of sigB was significantly increased
(10.2-fold) five minutes after vancomycin treatment. The tran-
scription of sigB was not detected in SJC1205 (sigB-deficient strain)
and was restored in SJC1206 (sigB-complemented strain). To
further confirm the activation of s
B, asp23 mRNA levels were
quantified. Consistent with the expression of sigB, the expression of
asp23 was significantly increased (9.8-fold) in strain SJC1200 10
minutes after vancomycin treatment, suggesting that s
B was
activated (Fig. 2B). The activation of asp23 was abolished in strain
SJC1205 and was restored in SJC1206. Vancomycin-stimulated
s
B activation was also observed in VRSA strains derived from the
strain COL and ATCC 49476 genetic backgrounds and in the
VISA strain Mu50 at the concentrations of 32 and 4 mg/ml,
respectively (data not shown).
Figure 2. Expression of sigB upon vancomycin treatment.
Changes in the transcription levels of the (A) sigB and (B) asp23 genes
upon vancomycin treatment determined using qRT-PCR. Representative
agarose gel electrophoresis images of RT-PCR assays are shown below
the bar chart. V0 and V32: 0 and 32 mg/ml vancomycin, respectively.
* P,0.05 compared to the untreated control cells.
doi:10.1371/journal.pone.0024472.g002
Figure 3. Expression of virulence genes upon vancomycin
treatment. Changes in the transcription levels of (A) fnbA and (B) hla
genes upon vancomycin treatment determined using qRT-PCR.
Representative agarose gel electrophoresis images of RT-PCR assays
are shown below the bar chart. * P,0.05 and ** P,0.005 compared to
the untreated control cells.
doi:10.1371/journal.pone.0024472.g003
Figure 1. Effects of different antibiotics with distinct modes of
action on asp23 transcription. (-): sample without treatment
(negative control); 42: heat shock at 42uC for five minutes (positive
control); V16 and V32: vancomycin at the concentrations of 16 and
3 mg/ml, respectively.
doi:10.1371/journal.pone.0024472.g001
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associated genes
The transcription of hla and fnbA mRNA over time in response
to vancomycin treatment was investigated using RT-PCR. The
greatest difference in the expression levels of fnbA and hla between
drug-treated and untreated cells was observed one hour after
vancomycin treatment, and this time point was used for further
qRT-PCR assays (Fig. S2). A significant increase in the
transcription level of fnbA (4.8-fold) was observed one hour after
treatment of vancomycin in strain SJC1200. The increased fnbA
expression was abolished in strain SJC1205 and was restored in
SJC1206 (Fig. 3A). However, hla expression was significantly
decreased (0.2-fold) after one hour of vancomycin treatment. The
decreased hla expression was not observed in strain SJC1205 and
was restored in SJC1206 (Fig. 3B).
Effect of vancomycin on the hemolytic activity
The decreased hla expression suggests that the hemolytic activity
of S. aureus is impaired following vancomycin treatment. A
hemolytic assay measuring contact hemolysis was performed to
evaluate the effect of vancomycin-induced s
B activity on
hemolysis. As expected, vancomycin treatment significantly
suppressed hemolysis by strains SJC1200 and SJC1206 and mildly
reduced hemolysis in the sigB-deficient strain SJC1205 (Fig. 4A
and 4B).
Effect of vancomycin-induced s
B activity on cytotoxicity
The pathogenicity of S. aureus involves the net expression of
different exotoxins and cell wall components. Whether the
vancomycin-induced s
B activity affected S. aureus pathogenicity
was investigated by a cytotoxicity assay. Because S. aureus is a
major pathogen of the airway, cytotoxicity was evaluated in
BEAS-2B cells using the MTT assay. When strains SJC1200 and
SJC1206 were challenged with vancomycin, the cell viability was
significantly decreased in a dose-dependent manner (Fig. 5A). The
viability of BEAS-2B cells co-cultured with SJC1200 decreased to
74% (P,0.05) upon treatment with vancomycin at 16 mg/ml and
further decreased to 57% (P,0.005) at 32 mg/ml. No considerable
cytotoxicity was detected by challenging strain SJC1205 under the
same conditions.
Vancomycin-enhanced fnbA expression suggests that the
increased cytotoxicity may result from an increase in bacterial
attachment to cells. A parallel cytotoxicity experiment was
performed in which the target of fibronectin-binding proteins,
fibronectin was blocked using antibodies. Vancomycin-enhanced
cytotoxicity was abolished among all of the three strains in the
presence of fibronectin antibodies (Fig. 5B). Cytotoxicity was not
observed in control cells cultured with different concentrations of
vancomycin or polyclonal fibronectin antibodies in the absence of
bacteria (Fig. 5A and 5B).
Discussion
In the present study, we demonstrated that s
B was activated
when S. aureus was exposed to sub-inhibitory concentrations of
antibiotics that target the cell wall (ampicillin and vancomycin) or
SXT. In particular, we focused on the effects of vancomycin
treatment on a VRSA strain. We demonstrated that vancomycin-
stimulated s
B is involved in the expression of virulence-associated
genes and the increase in cytotoxicity. A recent study also
indicated that the alternative sigma factor s
E, which is responsible
for the surface stress response, is activated by vancomycin in
Mycobacterium tuberculosis [27].
We demonstrated that only the cell-wall active antibiotics and
SXT acted as environmental stressors that induced s
B transcrip-
tion (Fig. 1). It has been reported that treatment with protein-
suppressing agents may not cause significant differences in the
expression of virulence factors in S. aureus [14,15]. We propose that
cell wall-targeting antibiotics and SXT trigger unknown receptors
Figure 4. Effect of vancomycin on hemolytic activity. (A) Quantitative hemolytic unit. (B) Hemolysis was observed in a flat-bottom 96-well
microtiter plate. Numerals shown on the figure represent the vancomycin concentration (mg/ml). PC: positive control; NC: negative control
(erythrocyte suspensions without bacterial inoculation). ** P,0.005 compared to the untreated control cells.
doi:10.1371/journal.pone.0024472.g004
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B activity. Activation of s
B by vancomycin was
observed in the SJC1200 strain (ATCC 12598 derivative), in the
VISA strain Mu50, and in all of the tested VRSA strains derived
from the strain COL and the ATCC 49476 genetic backgrounds
(data not shown), suggesting that antibiotic-induced s
B activity
occurs frequently. Strain 12598 was chosen for subsequent studies
because of its strong hemolysis and cytotoxicity in our previous
study. DNA sequence analysis indicated that there were no
mutations in the sigB operon of strain 12598 (data not shown).
Cheung and colleagues demonstrated the hyper-production of
a-hemolysin in a sigB mutant, implying a negative effect of s
B on
hla expression [28]. Restoring s
B activity to a s
B-impaired strain
decreased Hla expression [8]. Consistent with these findings,
vancomycin-activated s
B significantly suppressed hla expression,
thereby reducing hemolysis. In addition to exotoxins such as
hemolysins, cell wall-associated proteins, such as fibronectin-
binding proteins (FnBPs), are important virulence determinants.
The surface levels of FnBP were lower in a sigB-deficient strain,
suggesting that s
B regulates FnBP expression [29]. It has been
shown that the increased expression of FnBPs is related to the
diminished expression of Hla [30,31]. Our results are consistent
with previous findings in that increased fnbA transcription was
associated with decreased hla. Thus, the interplay between s
B
activation and the expression of hla and fnbA is associated with
vancomycin treatment. Although the expression of many virulence
factors in S. aureus is regulated by the agr-mediated temporal and
cell density-dependent regulatory pathways [9], vancomycin
treatment still had a significant and immediate effect on the
expression levels of virulence factors during the exponential
growth phase (Fig. S2). The rapid activation of s
B in response to
vancomycin stress may force virulence expression through cell
density-independent pathways. Generally speaking, the expression
of fnbA was increased over time in sigB
+ strains with or without
vancomycin treatment, whereas hla was increased up to two hours
after vancomycin treatment (Fig. S2).
A striking finding of the present study is that s
B was activated
by cell wall-targeting antibiotics and SXT in drug-resistant S.
aureus strains. This sigma factor may mediate the antibiotic-
activated signal, as well as other environmental stresses, to
downstream virulence determinants, leading to worse outcomes
in the clinical environment. The results from the cytotoxicity
assays reported herein reflect this concern. A significant decrease
in cell viability upon administration of increased concentrations of
vancomycin in the presence of drug-resistant S. aureus was
observed (Fig. 5). Cytotoxicity induced by vancomycin was not
observed when BEAS-2B cells were co-cultured with the sigB-
deficient S. aureus strain SJC1205, suggesting the key role of s
B in
responding to antibiotic stress. The rapid increase in the
prevalence of multidrug-resistant pathogenic bacteria and the
appearance of resistant strains following continuous selective
pressure suggest that improper antibiotic use may occur in the
clinical environment. Such improper use may be the result of
unsuitable initial antibiotic treatment, the development of drug-
resistant strains during long-term selective pressure or inappro-
priate treatment following misdiagnosis. Regardless, antibiotic-
enhanced pathogenicity makes subsequent treatment much more
difficult. A recent study indicated that the highest mean steady-
state concentrations of vancomycin for continuous and intermit-
tent infusion regimens were 24.88612.75 and 55.02617.36 mg/
ml, respectively, whereas the lowest concentrations were
19.89610.15 and 12.43612.86 mg/ml, respectively, in serum
[32]. Concentrations are expected to be even lower in tissues. As a
result, VISA strains could survive and enhance pathogenicity. Our
results indicate that s
B was activated in strain Mu50 after
treatment with a lower concentration of vancomycin (4 mg/ml,
data not shown), suggesting that the expression of s
B-associated
virulence genes might be altered.
The model strain used in the present study was derived from the
ATCC 12598 (Cowan I) genetic background, which has been
recognized as a protein A-overproducing and archetypal adherent
strain. This strain is also known to lack a variety of exotoxins such
as most staphylococcal enterotoxins, exfoliative toxins and toxic
shock syndrome toxin 1 [33]. Strain ATCC 12598 is often used as
a control strain in determining the invasive capacity and
cytotoxicity of other strains. It has been demonstrated that FnBP
expression is highly associated with the invasion of host cells,
particularly during the study of ATCC 12598 [34]. Following
vancomycin treatment, no obvious increase in exoprotein
secretion by strain SJC1200 was observed by SDS PAGE analysis
(data not shown), but there was a decrease in Hla expression. This
result suggests that the cytotoxicity caused by SJC1200 was mainly
due to the s
B-activated cell wall components, possibly FnBPs,
upon vancomycin treatment. A parallel study was performed using
Figure 5. Effect of vancomycin-treated VRSA on the cytotox-
icity. Cytotoxicity toward BEAS-2B cells inoculated with S. aureus strains
in the presence of different concentrations of vancomycin (A) without
or (B) with polyclonal fibronectin antibodies. ‘‘Cell only’’ indicates cells
cultured without bacteria to evaluate the cytotoxicity of vancomycin.
‘‘Ab+cell’’ indicates cells cultured with polyclonal fibronectin antibodies
to evaluate the cytotoxicity of the antibodies. * P,0.05 and ** P,0.005
compared to the untreated control cells.
doi:10.1371/journal.pone.0024472.g005
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and similar cytotoxicity results were observed. Based on many
studies, fnbA could have some role in invasion, but the overall
cytotoxicity (cell invasion and damage) is governed by various
toxins. Because SDS-PAGE is not a sensitive determinant of
protein secretion, the expression of trace exoproteins stimulated by
vancomycin may not be observable using a gel. In addition,
BEAS-2B cells may not be the best model for analyzing virulence,
particularly because they are less sensitive to Hla. However, the
blockage of fibronectin by antibodies leading to subsequent
reduction of cytotoxicity implies that vancomycin-enhanced
bacterial attachment plays an important role in pathogenesis, at
least in bronchial epithelial cells (Fig. 5B). The role of toxins
underlying cytotoxicity after bacterial attachment and invasion
needs to be investigated. Nevertheless, we propose that other s
B-
regulated exotoxins are overexpressed upon antibiotic treatment in
other drug-resistant strains.
In conclusion, we hypothesize that sub-MICs of antibiotics may
act as environmental stresses to activate the stress response sigma
factor, s
B. Although it has been reported that a number of
virulence-associated genes are regulated by s
B, the complexity of
the downstream global regulatory pathways shows the diversity of
virulence gene expression levels, not only within a single strain but
also among different lineages. The pathogenicity of S. aureus will be
the net effect of virulence-associated regulatory pathways and
strain dependence. Although we cannot give a definitive warning
about the antibiotic-triggered s
B-associated virulence factor
expression in pathogenic S. aureus because of strain variation, the
risk should be taken into consideration.
Supporting Information
Figure S1 Evaluation of the expression levels of sigB
and asp23 over time using RT-PCR. The agarose gel
electrophoresis image shows the time course of the expression of
sigB and asp23 in strains SJC1200, SJC1205, and SJC1206 without
(V0) or with (V32) vancomycin treatment using RT-PCR.
(TIF)
Figure S2 Evaluation of the expression levels of fnbA
and hla over time using RT-PCR. The agarose gel
electrophoresis image shows the time course of the expression of
fnbA and hla in strains SJC1200, SJC1205, and SJC1206 without
(V0) or with (V32) vancomycin treatment using RT-PCR.
(TIF)
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